Core42 Expands its AI Cloud Offering Using NVIDIA Accelerated Computing
Core42, a G42 company specializing in sovereign cloud, AI infrastructure, and digital services announced an expansion of its Next-Generation AI Cloud offering by deploying NVIDIA H100 Tensor Core GPUs in the UAE. This milestone establishes Core42 as the pioneer in the UAE to offer scalable AI compute resources, eliminating the need for customers to own physical infrastructure and providing the tools necessary to navigate complex data sovereignty and regulatory requirements.
As demand for AI-driven solutions accelerates across the world, access to sovereign AI infrastructure is critical for digital transformation, particularly for the public sector and regulated industries. To address this challenge, Core42 has deployed a NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems and HGX accelerated systems supported by Dell PowerEdge XE9680 with NVIDIA cards, delivering high-performance acceleration for AI, HPC, and data analytics workloads. This infrastructure allows significant performance gains for demanding applications and enterprise-scale generative AI. The expanded offering positions Core42 as a front-runner in the region to deploy advanced US compute technologies in its Regulated Technology Environment (RTE).
Core42 has made available locally the full NVIDIA DGX experience, leveraging the NVIDIA AI Enterprise software platform. Recently G42 announced with NVIDIA the establishment of a Climate Tech Lab in Abu Dhabi. This state-of-the-art facility builds on NVIDIA’s Earth-2 platform, a digital twin cloud platform that combines the power of AI, physical simulations and computer graphics to simulate and visualize weather and climate predictions at a global scale with unprecedented accuracy and speed, which will run on the locally deployed infrastructure. The lab intends to accelerate climate and weather predictions with interactive, AI-augmented, high-resolution simulation.
“Having witnessed the remarkable impact of our AI Cloud offering with our clients, we are thrilled to introduce NVIDIA H100 GPUs in the UAE,” said Adrian Hobbs, Chief Technology Officer at Core42.
Global supply chain constraints, the high cost of advanced digital infrastructure, and export control restrictions have limited access to AI compute power in the region. Coupled with Core42’s RTE framework, compliance with export control regulations as well as mitigation against risks of unauthorized access or technology diversion is also achieved. The innovative model delivers cost-effective scalability and cutting-edge technology enabling businesses and institutions to harness accelerated compute for inferencing, machine learning, rendering, and application acceleration.
Core42 also plans to deploy NVIDIA H200 Tensor Core GPUs that will be made available to further extend its AI Cloud offering around the globe.
“We are thrilled to announce this offering which promotes equitable access to high-performance compute infrastructure, empowering organizations of all sizes to run sophisticated AI models without the burden of costly on-premise deployments and investments. At Core42, our growing global footprint which includes deployments in the US, Europe, and now the UAE offers a variety of digital infrastructure options which help clients optimize training and inference economics,” said Edmondo Orlotti, Chief Growth Officer, Core42.
“We see tremendous opportunity in the Middle East and are working with leading organizations in the region to accelerate AI adoption. Our collaboration with Core42 provides businesses in the region secure and reliable access to world-class AI resources,” said Marc Domenech, Regional Director Enterprise for META region at NVIDIA.
Core42 is cementing its leadership role in advancing the region's AI ecosystem. This strategic move underscores Core42's commitment to driving innovation and ensuring the UAE's position at the vanguard of global technological advancements.
Core42 will be exhibiting at GITEX Global 2024. To experience Core42’s innovative products and solutions firsthand, visit us at Stand H18 – A30.
About Core42:
Core42, a G42 company, empowers individuals, enterprises, and nations to unlock the full potential of AI through its comprehensive enablement capabilities. As a leading provider of sovereign cloud, AI infrastructure, and digital services, our mission is to accelerate the achievements of others and help them reach their most ambitious goals.
To learn more, please visit www.core42.ai and follow Core42 LinkedIn, Core42 Instagram, Core42 X.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010544839/en/
Contacts
Zina Olabi, zina.olabi@core42.ai
Communications@core42.ai
For further information, visit www.core42.ai -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.core42.ai%2
F&esheet=54134183&newsitemid=20241010544839&lan=en-US&anchor=www.core42.ai&index
=7&md5=b92dda0459927874d43ddda5f1c40d53
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom